Volume | 255,663 |
|
|||||
News | - | ||||||
Day High | 11.62 | Low High |
|||||
Day Low | 10.745 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Shattuck Labs Inc | STTK | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
11.34 | 10.745 | 11.62 | 10.78 | 11.10 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
5,365 | 255,663 | $ 11.15 | $ 2,850,366 | - | 1.3301 - 11.62 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:42:08 | 1 | $ 11.3341 | USD |
Shattuck Labs Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
511.78M | 47.47M | - | 1.66M | -87.3M | -1.84 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Shattuck Labs News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical STTK Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 9.82 | 11.62 | 9.74 | 10.83 | 336,562 | 0.96 | 9.78% |
1 Month | 9.11 | 11.62 | 8.71 | 9.96 | 292,289 | 1.67 | 18.33% |
3 Months | 9.04 | 11.62 | 8.06 | 9.37 | 333,262 | 1.74 | 19.25% |
6 Months | 1.64 | 11.62 | 1.575 | 6.47 | 1,000,235 | 9.14 | 557.32% |
1 Year | 2.93 | 11.62 | 1.3301 | 6.31 | 514,963 | 7.85 | 267.92% |
3 Years | 37.60 | 37.60 | 1.3301 | 8.18 | 282,832 | -26.82 | -71.33% |
5 Years | 18.61 | 60.5162 | 1.3301 | 11.11 | 266,679 | -7.83 | -42.07% |
Shattuck Labs Description
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor. |